I would add that not only is it a long shot but use of a strategy where immune cells are stimulated enmass (polyclonal stimulation) vs cytokine use to boost stimulated cells is downright dangerous.
Maybe the drug's use has been well demonstrated and the mode of action in animal experimentation, but trans species could bring up many problems. Particularly in humans there would be potential contraindications.
One of two known mechanisms for action by VX-950 is to foil HCV's ability to block liver's immune response against the virus. It is not surprising to find the apparent synergy between 950 and IFNa. If you need literatures to find more, let me know.